LuGAdesAE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med2004; 23: 3105–3124.
2.
JansenJPCrawfordBBergmanG. Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. Value Health2008; 11: 956–964.
3.
CaldwellDMWeltonNJAdesAE. Mixed treatment comparison analysis provides internally coherent treatment effect estimates based on overviews of reviews and can reveal inconsistency. J Clin Epidemiol2010; 63: 875–882.
4.
JansenJPNaciH. Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers. BMC Med2013; 11: 159.
5.
LeeAW. Review of mixed treatment comparisons in published systematic reviews shows marked increase since 2009. J Clin Epidemiol2014; 67: 138–143.
6.
HutchinsonMFoxRJHavrdovaE. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing–remitting multiple sclerosis: A systematic review and mixed treatment comparison. Curr Med Res Opin2014; 30: 613–627.
7.
FoxRJMillerDHPhillipsJT. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med2012; 367: 1087–1097.
8.
CohenJABarkhofFComiG. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med2010; 362: 402–415.
